Evrysdi risdiplam powder for oral solution package insert: dosage, administration, contraindications and safety for spinal muscular atrophy (SMA).
Evrysdi (risdiplam) powder for oral solution is used to treat spinal muscular atrophy (SMA) in patients aged 16 days and older. Each bottle contains 60 mg of risdiplam and is reconstituted by a healthcare professional into an oral solution at 0.75 mg/mL.
The insert gives the once-daily dose by age and body weight, administration with the provided oral syringe, and contraindications for patients allergic to risdiplam or any excipient. It also covers precautions including embryo-fetal toxicity, contraception, and use in pregnancy, breastfeeding, children and older adults. This manual is written in Chinese.
| Content per bottle | 60 mg risdiplam |
|---|---|
| Molecular formula | C22H23N7O |
| Molecular weight | 401.46 |
| Reconstituted concentration | 0.75 mg/mL |
It treats spinal muscular atrophy (SMA) in patients aged 16 days and older.
The recommended dose depends on age and body weight.
It is contraindicated in patients known to be allergic to risdiplam or any excipient.
Pregnant women should not use risdiplam during pregnancy unless the benefit to the mother outweighs the potential risk to the fetus.